S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Sponsor
Southwest Oncology Group (Other)
Overall Status
Completed
CT.gov ID
NCT00004217
Collaborator
National Cancer Institute (NCI) (NIH)
55
90
72.9
0.6
0

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs.

PURPOSE: Phase II trial to study the effectiveness of PSC 833, daunorubicin, and cytarabine in treating older patients who have newly diagnosed acute myeloid leukemia.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

OBJECTIVES: I. Determine the safety and efficacy of daunorubicin and cytarabine by continuous infusion and PSC 833 in patients over age 56 with newly diagnosed acute myeloid leukemia. II. Determine the frequency and severity of toxicities of this regimen in these patients. III. Determine the frequency and prognosis of functional and phenotypic P-glycoprotein expression, cytogenetics, and pharmacokinetics in this population.

OUTLINE: This is a multicenter study. Patients receive induction chemotherapy consisting of PSC 833 IV over 2 hours on day 1, then continuously for 96 hours; daunorubicin IV continuously on days 1-3; and cytarabine IV continuously on days 1-7. Filgrastim (G-CSF) or sargramostim (GM-CSF) is administered subcutaneously (SQ) or IV beginning on day 15 and continuing until blood counts recover or day 21. If patients do not achieve complete remission after one course, a second course is administered. Patients who achieve A1 bone marrow, B1 peripheral blood, and C1 extramedullary disease status after 1 or 2 courses of induction chemotherapy proceed to consolidation therapy, which begins upon recovery from induction therapy. Consolidation therapy consists of PSC 833 over 2 hours on day 1, daunorubicin IV over 1-5 minutes on days 1 and 2, and cytarabine IV continuously on days 1-5. Treatment repeats for a total of 2 courses. Patients are followed every 6 months for 2 years and then annually for 3 years.

PROJECTED ACCRUAL: A total of 20-55 patients will be accrued for this study within 8-9 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
55 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older
Study Start Date :
Feb 1, 2000
Actual Primary Completion Date :
May 1, 2001
Actual Study Completion Date :
Mar 1, 2006

Outcome Measures

Primary Outcome Measures

  1. response [after induction therapy is completed]

Eligibility Criteria

Criteria

Ages Eligible for Study:
56 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

DISEASE CHARACTERISTICS: Morphologically confirmed acute myeloid leukemia (AML) No M3 AML or blastic phase chronic myelogenous leukemia Must be registered on protocols SWOG-9007 and SWOG-9910

PATIENT CHARACTERISTICS: Age: 56 and over Performance status: Zubrod 0-3 Life expectancy:

Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT/SGPT no greater than 4 times ULN Renal: Creatinine no greater than 1.5 times ULN Creatinine clearance greater than 40 mL/min Cardiovascular: LVEF at least 50% by MUGA or echocardiogram No unstable cardiac arrhythmias or angina Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except: Adequately treated basal cell or squamous cell skin cancer Carcinoma in situ of the cervix Adequately treated stage I or II cancer in complete remission

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for acute leukemia Prior hydroxyurea to control high cell counts allowed At least 30 days since prior low dose cytarabine (less than 100 mg/m2/day) for myelodysplastic syndrome and recovered Single dose of prior or concurrent (with induction chemotherapy) intrathecal chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

Contacts and Locations

Locations

Site City State Country Postal Code
1 MBCCOP - University of South Alabama Mobile Alabama United States 36688
2 CCOP - Greater Phoenix Phoenix Arizona United States 85006-2726
3 Veterans Affairs Medical Center - Phoenix (Hayden) Phoenix Arizona United States 85012
4 Veterans Affairs Medical Center - Tucson Tucson Arizona United States 85723
5 Arizona Cancer Center Tucson Arizona United States 85724
6 University of Arkansas for Medical Sciences Little Rock Arkansas United States 72205
7 Veterans Affairs Medical Center - Little Rock (McClellan) Little Rock Arkansas United States 72205
8 Veterans Affairs Medical Center - Long Beach Long Beach California United States 90822
9 USC/Norris Comprehensive Cancer Center Los Angeles California United States 90033-0800
10 Jonsson Comprehensive Cancer Center, UCLA Los Angeles California United States 90095-1781
11 Beckman Research Institute, City of Hope Los Angeles California United States 91010
12 Veterans Affairs Outpatient Clinic - Martinez Martinez California United States 94553
13 CCOP - Bay Area Tumor Institute Oakland California United States 94609-3305
14 Chao Family Comprehensive Cancer Center Orange California United States 92868
15 University of California Davis Medical Center Sacramento California United States 95817
16 UCSF Cancer Center and Cancer Research Institute San Francisco California United States 94115-0128
17 Veterans Affairs Medical Center - San Francisco San Francisco California United States 94121
18 CCOP - Santa Rosa Memorial Hospital Santa Rosa California United States 95403
19 David Grant Medical Center Travis Air Force Base California United States 94535
20 Veterans Affairs Medical Center - Denver Denver Colorado United States 80220
21 University of Colorado Cancer Center Denver Colorado United States 80262
22 CCOP - Atlanta Regional Atlanta Georgia United States 30342-1701
23 Cancer Research Center of Hawaii Honolulu Hawaii United States 96813
24 CCOP - Central Illinois Decatur Illinois United States 62526
25 Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) Hines Illinois United States 60141
26 Loyola University Medical Center Maywood Illinois United States 60153
27 University of Kansas Medical Center Kansas City Kansas United States 66160-7357
28 CCOP - Wichita Wichita Kansas United States 67214-3882
29 Veterans Affairs Medical Center - Wichita Wichita Kansas United States 67218
30 Veterans Affairs Medical Center - Lexington Lexington Kentucky United States 40511-1093
31 Albert B. Chandler Medical Center, University of Kentucky Lexington Kentucky United States 40536-0084
32 MBCCOP - LSU Medical Center New Orleans Louisiana United States 70112
33 Tulane University School of Medicine New Orleans Louisiana United States 70112
34 Veterans Affairs Medical Center - New Orleans New Orleans Louisiana United States 70112
35 Louisiana State University Health Sciences Center - Shreveport Shreveport Louisiana United States 71130-3932
36 Veterans Affairs Medical Center - Shreveport Shreveport Louisiana United States 71130
37 Boston Medical Center Boston Massachusetts United States 02118
38 Veterans Affairs Medical Center - Boston (Jamaica Plain) Jamaica Plain Massachusetts United States 02130
39 Veterans Affairs Medical Center - Ann Arbor Ann Arbor Michigan United States 48105
40 University of Michigan Comprehensive Cancer Center Ann Arbor Michigan United States 48109-0752
41 Veterans Affairs Medical Center - Detroit Detroit Michigan United States 48201-1932
42 Barbara Ann Karmanos Cancer Institute Detroit Michigan United States 48201
43 Henry Ford Hospital Detroit Michigan United States 48202
44 CCOP - Grand Rapids Clinical Oncology Program Grand Rapids Michigan United States 49503
45 Providence Hospital - Southfield Southfield Michigan United States 48075-9975
46 Veterans Affairs Medical Center - Biloxi Biloxi Mississippi United States 39531-2410
47 University of Mississippi Medical Center Jackson Mississippi United States 39216-4505
48 Veterans Affairs Medical Center - Jackson Jackson Mississippi United States 39216
49 Keesler Medical Center - Keesler AFB Keesler AFB Mississippi United States 39534-2576
50 Veterans Affairs Medical Center - Kansas City Kansas City Missouri United States 64128
51 CCOP - Kansas City Kansas City Missouri United States 64131
52 St. Louis University Health Sciences Center Saint Louis Missouri United States 63110-0250
53 CCOP - St. Louis-Cape Girardeau Saint Louis Missouri United States 63141
54 CCOP - Cancer Research for the Ozarks Springfield Missouri United States 65807
55 CCOP - Montana Cancer Consortium Billings Montana United States 59101
56 Veterans Affairs Medical Center - Albuquerque Albuquerque New Mexico United States 87108-5138
57 MBCCOP - University of New Mexico HSC Albuquerque New Mexico United States 87131
58 Veterans Affairs Medical Center - Brooklyn Brooklyn New York United States 11209
59 Herbert Irving Comprehensive Cancer Center New York New York United States 10032
60 Barrett Cancer Center, The University Hospital Cincinnati Ohio United States 45219
61 Veterans Affairs Medical Center - Cincinnati Cincinnati Ohio United States 45220-2288
62 Cleveland Clinic Cancer Center Cleveland Ohio United States 44195
63 CCOP - Columbus Columbus Ohio United States 43206
64 Veterans Affairs Medical Center - Dayton Dayton Ohio United States 45428
65 CCOP - Dayton Kettering Ohio United States 45429
66 Oklahoma Medical Research Foundation Oklahoma City Oklahoma United States 73104
67 Veterans Affairs Medical Center - Oklahoma City Oklahoma City Oklahoma United States 73104
68 Oregon Cancer Center at Oregon Health Sciences University Portland Oregon United States 97201-3098
69 Veterans Affairs Medical Center - Portland Portland Oregon United States 97207
70 CCOP - Columbia River Program Portland Oregon United States 97213
71 CCOP - Greenville Greenville South Carolina United States 29615
72 CCOP - Upstate Carolina Spartanburg South Carolina United States 29303
73 Veterans Affairs Medical Center - Dallas Dallas Texas United States 75216
74 Simmons Cancer Center - Dallas Dallas Texas United States 75235-9154
75 Brooke Army Medical Center Fort Sam Houston Texas United States 78234
76 University of Texas Medical Branch Galveston Texas United States 77555-1329
77 University of Texas - MD Anderson Cancer Center Houston Texas United States 77030
78 Texas Tech University Health Science Center Lubbock Texas United States 79423
79 University of Texas Health Science Center at San Antonio San Antonio Texas United States 78284-7811
80 Veterans Affairs Medical Center - San Antonio (Murphy) San Antonio Texas United States 78284
81 Veterans Affairs Medical Center - Temple Temple Texas United States 76504
82 CCOP - Scott and White Hospital Temple Texas United States 76508
83 Huntsman Cancer Institute Salt Lake City Utah United States 84132
84 Veterans Affairs Medical Center - Salt Lake City Salt Lake City Utah United States 84148
85 CCOP - Southwestern Vermont Regional Cancer Center Bennington Vermont United States 05201
86 CCOP - Virginia Mason Research Center Seattle Washington United States 98101
87 Swedish Cancer Institute Seattle Washington United States 98104
88 Veterans Affairs Medical Center - Seattle Seattle Washington United States 98108
89 CCOP - Northwest Tacoma Washington United States 98405-0986
90 BC Cancer Agency Vancouver British Columbia Canada V5Z 4E6

Sponsors and Collaborators

  • Southwest Oncology Group
  • National Cancer Institute (NCI)

Investigators

  • Study Chair: Thomas R. Chauncey, MD, PhD, VA Puget Sound Health Care System

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00004217
Other Study ID Numbers:
  • S9918
  • S9918
  • U10CA032102
First Posted:
Jun 18, 2004
Last Update Posted:
Mar 6, 2015
Last Verified:
Mar 1, 2015

Study Results

No Results Posted as of Mar 6, 2015